Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabis sativa oil—often called hemp oil or CBD oil—is increasingly explored as a potential therapy for Fibromyalgia Syndrome (FMS). The rationale for its use is rooted in the interactions of cannabinoids with the human endocannabinoid system, which is involved in pain modulation and immune response. Some scientific studies and early clinical trials suggest that cannabinoids, including cannabidiol (CBD) derived from Cannabis sativa, may help alleviate chronic pain, improve sleep disturbances, and reduce anxiety—symptoms commonly associated with fibromyalgia.

However, the strength of the scientific evidence remains modest. A handful of small-scale clinical trials and observational studies have reported improvements in pain levels and quality of life for FMS patients using cannabis-based products, but these studies often suffer from limitations such as small sample sizes, lack of blinding, and short durations. For example, a 2019 observational study found that medical cannabis users with fibromyalgia reported a significant reduction in pain and symptom severity. Conversely, systematic reviews have concluded that while some patients may benefit, the evidence is not robust enough to draw definitive conclusions about efficacy or safety.

In summary, while the use of Cannabis sativa oil for fibromyalgia is based on some scientific investigation and biological plausibility, the overall quality and quantity of evidence is still limited. More large-scale, rigorous randomized controlled trials are needed to determine its true efficacy and safety for FMS patients.

More about cannabis sativa oil
More about Fibromyalgia Syndrome

Other ingredients used for Fibromyalgia Syndrome

Other health conditions supported by cannabis sativa oil

Products containing cannabis sativa oil

Pure Encapsulations Hemp extract VESIsorb®